Advertisement

Investigational New Drugs

, Volume 21, Issue 1, pp 109–111 | Cite as

Phase II Study of Single Agent Paclitaxel in Adult Patients with Relapsed Acute Lymphocytic Leukemia

  • Dawn E. Colburn
  • Deborah A. Thomas
  • Francis J. Giles
Article

Abstract

Background: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. Methods: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24 -h intravenous infusion repeated every 3–4 weeks. Results: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. Conclusion: The study paclitaxel regimen was ineffective in refractory adult ALL.

paclitaxel refractory acute lymphocytic leukemia adult 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18: 547–561, 2000Google Scholar
  2. 2.
    Gangemi RM, Tiso M, Marchetti C, Severi AB, Fabbi M: Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemother Pharmacol 36: 385–392, 1995Google Scholar
  3. 3.
    Munker R, Kantarjian H, O'Brien S, Keating M, Andreeff M, Estey EH: Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule. Acta Haematol 99: 106–108, 1998Google Scholar
  4. 4.
    Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC: Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 49: 4640–4647, 1989Google Scholar
  5. 5.
    Pathan N, Aime-Sempe C, Kitada S, Haldar S, Reed JC: Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1. Neoplasia 3: 70–79, 2001Google Scholar
  6. 6.
    Senderowicz AM: Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy. Cancer Chemother Biol Response Modif 19: 165–188, 2001Google Scholar
  7. 7.
    Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM: Phase I trial of 72–hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19: 2319–2333, 2001Google Scholar
  8. 8.
    Tolcher AW: Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol 28: 67–70, 2001Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Dawn E. Colburn
    • 1
  • Deborah A. Thomas
    • 1
  • Francis J. Giles
    • 1
  1. 1.Department of LeukemiaThe University of Texas, M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations